BMNDF - Biomind stock rises 11% on license to start project for microneedle use in drug delivery

• Biomind Labs ( OTCQB:BMNDF ) stock rose ~11% on Sept. 27 after the company said it received a controlled substances license to start production of a novel transdermal drug delivery system.
• Biomind Labs and Queen’s University of Belfast will begin an eight-month project to produce and evaluate novel rapidly-dissolving and sustained-release hydrogel-forming microneedle arrays for transdermal delivery of Biomind's psychedelic compounds: N, N-dimethyltryptamine (DMT), 5-methoxyN, N-dimethyltryptamine (5-MeO-DMT) and mescaline, the company said in a Sept. 27 press release.
• The company added that the use of polymeric microneedle array patches (MAPs) is an attractive way of delivering drugs through the skin.
• "As we continue expanding our operations in the United Kingdom, partnering with Queen’s University of Belfast, a global leader in rapidly-dissolving and sustained-release hydrogel-forming microneedles, can provide us with a first mover advantage in offering a novel drug delivery system where the release can be controlled," said Biomind CEO Alejandro Antalich.

For further details see: